---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-053482"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2026-05-01T23:59:59+00:00"
generated_at: "2026-05-15T00:17:00.386026+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Esperion acquired by ARCHIMED for $3.16/share plus up to $100M in milestone payments

## Summary
- Cash $3.16/share + 1 CVR/share; aggregate milestone payments up to $100M based on net sales.
- Milestone triggers: $40M if 2027 U.S. sales of bempedoic acid products >$350M; $60M if ENBUMYST sales >=$160M/year through 2030.
- Close expected Q3 2026; conditions include stockholder approval, HSR clearance, and non-U.S. antitrust.
- Board unanimously recommends; termination fees: $34.15M (Esperion), $68.3M (ARCHIMED).
- Financing from ARCHIMED affiliates and third-party debt; no financing condition.

## SEC filing metadata
- accession: 0001104659-26-053482
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2026-05-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000110465926053482/0001104659-26-053482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000110465926053482/tm2613340d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-053482
- JSON: https://secwatch.observer/filing/0001104659-26-053482.json
- Plain text: https://secwatch.observer/filing/0001104659-26-053482.txt

## Source-grounded claims
- claim_id: 402c101ecf96fc6eb017360478b65f1fa90c3482
  claim: Esperion Therapeutics, Inc. entered into Agreement and Plan of Merger with Essence Parent Inc. valued at Merger consideration of $3.16 per share plus contingent value rights (effective 2026-05-01).
  evidence_excerpt: On May 1, 2026, Esperion Therapeutics, Inc. (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Essence Parent Inc., a Delaware corporation (“ Parent ”), and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent (“ MergerCo ”), pursuant to which, subject to the terms and conditions thereof, MergerCo will merge with and into the Company with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the “ Merger ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000110465926053482/0001104659-26-053482-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.